双嘧达莫联合厄贝沙坦对IgA肾病的疗效及其安全性分析 : = Analysis of Dipyridamole Combined with Irbesartan Treatment on IgA Nephropathy and its Safety
目的探究双嘧达莫联合厄贝沙坦对Ig A肾病的疗效及其安全性。方法采取回顾性分析方法对遵义医学院第五附属(珠海)医院2013年7月—2016年7月Ig A肾病患者88例资料进行收集分析,随机分为单药组和联合组。单药组采用单纯厄贝沙坦治疗;联合组采用双嘧达莫联合厄贝沙坦治疗。比较两组患者Ig A肾病治疗效果;治疗前后24 h尿蛋白、血肌酐;不良反应发生率。结果联合组患者Ig A肾病治疗效果比单药组高,P<0.05;治疗前两组患者24 h尿蛋白、血肌酐差异不显著,P>0.05;联合组治疗后24 h尿蛋白、血肌酐比单药组好,P<0.05;联合组不良反应发生率和单药组差异不显著,P>0.05。结论双嘧达莫联合厄贝沙坦对Ig A肾病的疗效及其安全性良好,可改善肾功能,无明显副作用,值得推广。.
Objective To explore the effect of dipyridamole combined with irbesartan on Ig A nephropathy and its safety.Methods Retrospective methods analysis was performed on 88 patients with Ig A nephropathy in our hospital from July 2013 to July 2016,Single drug group were treated with irbesartan treatment; combination group received dipyridamole combined with irbesartan in the treatment of.Comparison of two groups of patients with Ig A nephropathy treatment effect before and after treatment for 24 hours urine protein,serum creatinine.Results The therapeutic effect of the combined group of patients with Ig A nephropathy than the single drug group,P < 0.05; two groups of patients before treatment and 24 hours urine protein,serum creatinine was not significant,P > 0.05; combined treatment group after 24 hours urine protein,serum creatinine than the single drug group,P < 0.05;united group of adverse reaction difference and the rate of single drug group was not significant,P >0.05.Conclusion Dipyridamole combined with irbesartan treatment on Ig A nephropathy and its safety is good,can improve renal function and no obvious side effects,worthy of promotion..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017-03-30 16:57 2017 |
|---|---|
| Erschienen: |
2017-03-30 16:57 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2017 |
|---|---|
| Enthalten in: |
Guang dong wei liang yuan su ke xue - (2017), 03 vom: 30 16:57. März, Seite 35-37 Original Letters: Enthalten in 广东微量元素科学 (DE-600)2996160-9 (DE-600)2996160-9 广东省广州市 |
| Reihe: |
China Academic Journals (CAJ), E, 医药卫生科技 = Medicine & Public Health |
|---|
| Sprache: |
Chinesisch |
|---|
| Weiterer Titel: |
Analysis of Dipyridamole Combined with Irbesartan Treatment on IgA Nephropathy and its Safety |
|---|
| Beteiligte Personen: |
黄颖斌 [VerfasserIn] |
|---|
| Links: |
oversea.cnki.net [lizenzpflichtig] |
|---|
| Themen: |
医药、卫生 |
|---|
| Anmerkungen: |
Author info:HUANG Yingbin;The Fifth Affiliated Hospital of Zunyi Medical College (Zhuhai) |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
CAJ559457006 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | CAJ559457006 | ||
| 003 | DE-627 | ||
| 005 | 20230117062829.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 221225s2017 cc |||||o 00| ||chi c | ||
| 035 | |a (DE-627)CAJ559457006 | ||
| 035 | |a (SBB-XA)CAJ_GWYS201703008 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 044 | |c XB-CN | ||
| 084 | |a ASIEN |q DE-1a |2 fid | ||
| 084 | |a R692.31 |2 clc | ||
| 100 | 0 | |a 黄颖斌 |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a 双嘧达莫联合厄贝沙坦对IgA肾病的疗效及其安全性分析 |b = Analysis of Dipyridamole Combined with Irbesartan Treatment on IgA Nephropathy and its Safety |
| 246 | 3 | 1 | |a Analysis of Dipyridamole Combined with Irbesartan Treatment on IgA Nephropathy and its Safety |
| 264 | 1 | |c 2017-03-30 16:57 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 490 | 0 | |a China Academic Journals (CAJ) |a E |a 医药卫生科技 = Medicine & Public Health | |
| 500 | |a Author info:HUANG Yingbin;The Fifth Affiliated Hospital of Zunyi Medical College (Zhuhai) | ||
| 520 | |a 目的探究双嘧达莫联合厄贝沙坦对Ig A肾病的疗效及其安全性。方法采取回顾性分析方法对遵义医学院第五附属(珠海)医院2013年7月—2016年7月Ig A肾病患者88例资料进行收集分析,随机分为单药组和联合组。单药组采用单纯厄贝沙坦治疗;联合组采用双嘧达莫联合厄贝沙坦治疗。比较两组患者Ig A肾病治疗效果;治疗前后24 h尿蛋白、血肌酐;不良反应发生率。结果联合组患者Ig A肾病治疗效果比单药组高,P<0.05;治疗前两组患者24 h尿蛋白、血肌酐差异不显著,P>0.05;联合组治疗后24 h尿蛋白、血肌酐比单药组好,P<0.05;联合组不良反应发生率和单药组差异不显著,P>0.05。结论双嘧达莫联合厄贝沙坦对Ig A肾病的疗效及其安全性良好,可改善肾功能,无明显副作用,值得推广。 | ||
| 520 | |a Objective To explore the effect of dipyridamole combined with irbesartan on Ig A nephropathy and its safety.Methods Retrospective methods analysis was performed on 88 patients with Ig A nephropathy in our hospital from July 2013 to July 2016,Single drug group were treated with irbesartan treatment; combination group received dipyridamole combined with irbesartan in the treatment of.Comparison of two groups of patients with Ig A nephropathy treatment effect before and after treatment for 24 hours urine protein,serum creatinine.Results The therapeutic effect of the combined group of patients with Ig A nephropathy than the single drug group,P < 0.05; two groups of patients before treatment and 24 hours urine protein,serum creatinine was not significant,P > 0.05; combined treatment group after 24 hours urine protein,serum creatinine than the single drug group,P < 0.05;united group of adverse reaction difference and the rate of single drug group was not significant,P >0.05.Conclusion Dipyridamole combined with irbesartan treatment on Ig A nephropathy and its safety is good,can improve renal function and no obvious side effects,worthy of promotion. | ||
| 610 | 2 | 4 | |a 遵义医学院第五附属(珠海)医院 |
| 650 | 4 | |a 泌尿科学 | |
| 650 | 4 | |a 外科学 | |
| 650 | 4 | |a 医药、卫生 | |
| 650 | 4 | |a Urology | |
| 650 | 4 | |a 医药卫生科技 | |
| 650 | 4 | |a Medicine & Public Health | |
| 650 | 4 | |a 双嘧达莫 | |
| 650 | 4 | |a 厄贝沙坦 | |
| 650 | 4 | |a IgA肾病 | |
| 650 | 4 | |a 疗效 | |
| 650 | 4 | |a 安全性 | |
| 650 | 4 | |a dipyridamole | |
| 650 | 4 | |a irbesartan | |
| 650 | 4 | |a IgA nephropathy | |
| 650 | 4 | |a efficacy | |
| 650 | 4 | |a safety | |
| 773 | 0 | 8 | |6 880-01 |i Enthalten in |t Guang dong wei liang yuan su ke xue |d Guang dong sheng guang zhou shi, 1994 |g (2017), 03 vom: 30 16:57. März, Seite 35-37 |h Online-Ressource |w (DE-627)CAJ149523920 |w (DE-600)2996160-9 |7 nnns |
| 773 | 1 | 8 | |g year:2017 |g number:03 |g day:30 16:57 |g month:03 |g pages:35-37 |
| 856 | 4 | 0 | |u http://erf.sbb.spk-berlin.de/han/caj/oversea.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&filename=GWYS201703008 |x Verlag |y CrossAsia Link |z Deutschlandweit zugänglich |
| 856 | 4 | 0 | |u https://oversea.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&filename=GWYS201703008 |x Verlag |z lizenzpflichtig |
| 880 | 0 | 8 | |6 773-01/Hans |i Enthalten in |t 广东微量元素科学 |d 广东省广州市 |h Online-Ressource |w (DE-627)CAJ149523920 |w (DE-600)2996160-9 |7 nnns |
| 912 | |a ZDB-1-CAJ | ||
| 912 | |a GBV_NL_CAJ | ||
| 912 | |a FID-ASIEN | ||
| 912 | |a SSG-OLC-OA3.1 | ||
| 912 | |a SSG-OLC-CAJ | ||
| 936 | u | w | |j 2017 |e 03 |b 30 16:57 |c 03 |h 35-37 |
| 951 | |a AR | ||
| 952 | |j 2017 |e 03 |b 30 16:57 |c 03 |h 35-37 | ||
| 980 | |2 11 |1 01 |x 0001 |b 578956799 |c 00 |f 5:FIDXASIA |d --%%-- |e --%%-- |j --%%-- |y k |z 25-12-22 | ||
| 981 | |2 11 |1 01 |x 0001 |r http://erf.sbb.spk-berlin.de/han/caj/oversea.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&filename=GWYS201703008 | ||